These findings suggest that the ALMS1‐IT1‐STAT3 axis represents a novel therapeutic target in CRC, providing insights into potential interventions aimed at disrupting this pathway to inhibit tumour progression and improve patient outcomes. Here, STAT3 is linked to neoplasm.